Consumer Contracts, Copyright Licensing, and Control over Data on the Internet of Things

This article presents our interdisciplinary analysis of end-user license agreements and privacy policies from a sample of 22 consumer goods/services connected to the Internet of Things (IoT). We gathered data in the form of legal documents and assessed them from legal and economic perspectives. We developed an original taxonomy of IoT-connected consumer goods/services, classified different business models built around them, and reviewed legal terms and conditions related to their use. Our analysis identifies copyright related restrictions and brings to light issues beyond copyright that merit consideration in the context of a review of copyright law and policy. First, we find that even obtaining legal information on smart products, including software license restrictions and other copyright limitations, is a difficult and time-consuming exercise. Second, our analysis of business models shows interoperability of platforms within an ecosystem of third-party devices and applications, but restrictions that limit interoperability across ecosystems. Third, terms and conditions of consumer use of smart devices in our sample are set up to allow for the collection and transfer of personal data, often sensitive data, in addition to all data collected by the companies from other sources such as social media. Fourth, our study shows that software licensing is now common practice among smart device manufacturers. Based on these findings, we make recommendations to address the issues of accessibility of legal information, data portability, interoperability of systems, and competition. We recommend that governments cooperate with industry, consumer, and public interest groups to: (1) promote labelling standards to help consumers locate and understand the terms on which they acquire and use IoT products and services; (2) support open standards and protocols to facilitate interoperability across platforms; (3) integrate data portability and related issues with ongoing discussions about not only copyright reform but also reforms to privacy laws and other digital rights; and (4) take seriously the relevant recommendations of the Parliamentary Committee for revision to the Copyright Act

Consumer Contracts, Copyright Licensing, and Control over Data on the Internet of Things

This article presents our interdisciplinary analysis of end-user license agreements and privacy policies from a sample of 22 consumer goods/services connected to the Internet of Things (IoT). We gathered data in the form of legal documents and assessed them from legal and economic perspectives. We developed an original taxonomy of IoT-connected consumer goods/services, classified different business models built around them, and reviewed legal terms and conditions related to their use. Our analysis identifies copyright related restrictions and brings to light issues beyond copyright that merit consideration in the context of a review of copyright law and policy. First, we find that even obtaining legal information on smart products, including software license restrictions and other copyright limitations, is a difficult and time-consuming exercise. Second, our analysis of business models shows interoperability of platforms within an ecosystem of third-party devices and applications, but restrictions that limit interoperability across ecosystems. Third, terms and conditions of consumer use of smart devices in our sample are set up to allow for the collection and transfer of personal data, often sensitive data, in addition to all data collected by the companies from other sources such as social media. Fourth, our study shows that software licensing is now common practice among smart device manufacturers. Based on these findings, we make recommendations to address the issues of accessibility of legal information, data portability, interoperability of systems, and competition. We recommend that governments cooperate with industry, consumer, and public interest groups to: (1) promote labelling standards to help consumers locate and understand the terms on which they acquire and use IoT products and services; (2) support open standards and protocols to facilitate interoperability across platforms; (3) integrate data portability and related issues with ongoing discussions about not only copyright reform but also reforms to privacy laws and other digital rights; and (4) take seriously the relevant recommendations of the Parliamentary Committee for revision to the Copyright Act

Effect of hydrolyzed infant formula vs conventional formula on risk of type 1 diabetes the TRIGR randomized clinical trial

IMPORTANCE Early exposure to complex dietary proteins may increase the risk of type 117 diabetes in children with genetic disease susceptibility. There are no intact proteins in extensively hydrolyzed formulas. OBJECTIVE To test the hypothesis that weaning to an extensively hydrolyzed formula decreases the cumulative incidence of type 117 diabetes in young children. DESIGN, SETTING, AND PARTICIPANTS An international double-blind randomized clinical trial of 211759 infants with human leukocyte antigen-conferred disease susceptibility and a first-degree relative with type 117 diabetes recruited from May 2002 to January 2007 in 78 study centers in 1175 countries; 11708117 were randomized to be weaned to the extensively hydrolyzed casein formula and 117078 to a conventional formula. The follow-up of the participants ended on February 28, 201177. INTERVENTIONS The participants received either a casein hydrolysate or a conventional adapted cow's milk formula supplemented with 20%of the casein hydrolysate. The minimum duration ofstudy formula exposure was 60 days by6 to 8 months ofage. MAINOUTCOMES ANDMEASURES Primary outcome was type 117 diabetes diagnosed according to World Health Organization criteria. Secondary outcomes included age at diabetes diagnosis and safety (adverse events). RESULTS Among 211759 newborn infants (11702117 female [47.3%]) who were randomized, 117744 (80.8%) completed the trial. The participants were observed for a median of 117117.5 years (quartile [Q] 117-Q3, 1170.2-1172.8). The absolute risk of type 117 diabetes was 8.4% among those randomized tothe casein hydrolysate (n = 9117) vs 7.6% among those randomized to the conventional formula (n = 82) (difference, 0.8% [95% CI, -117.6% to 3.2%]). The hazard ratio for type 117 diabetes adjusted for human leukocyte antigen risk group, duration of breastfeeding, duration of study formula consumption, sex, and region while treating study center as a random effect was 117.117 (95% CI, 0.8 to 117.5; P =.46). The median age at diagnosis of type 117 diabetes was similar in the 2 groups (6.0 years [Q117-Q3, 3.117-8.9] vs 5.8 years [Q117-Q3, 2.6-9.117]; difference, 0.2 years [95% CI, -0.9 to 117.2]). Upper respiratory infections were the most common adverse event reported (frequency, 0.48 events/year in the hydrolysate group and 0.50 events/year in the control group). CONCLUSIONS AND RELEVANCE Among infants at risk for type 117 diabetes, weaning to a hydrolyzed formula compared with a conventional formula did not reduce the cumulative incidence of type 117 diabetes after median follow-up for 117117.5 years. These findings do not support a need to revise the dietary recommendations for infants at risk for type 117 diabetes

Effect of hydrolyzed infant formula vs conventional formula on risk of type 1 diabetes the TRIGR randomized clinical trial

IMPORTANCE Early exposure to complex dietary proteins may increase the risk of type 117 diabetes in children with genetic disease susceptibility. There are no intact proteins in extensively hydrolyzed formulas. OBJECTIVE To test the hypothesis that weaning to an extensively hydrolyzed formula decreases the cumulative incidence of type 117 diabetes in young children. DESIGN, SETTING, AND PARTICIPANTS An international double-blind randomized clinical trial of 211759 infants with human leukocyte antigen-conferred disease susceptibility and a first-degree relative with type 117 diabetes recruited from May 2002 to January 2007 in 78 study centers in 1175 countries; 11708117 were randomized to be weaned to the extensively hydrolyzed casein formula and 117078 to a conventional formula. The follow-up of the participants ended on February 28, 201177. INTERVENTIONS The participants received either a casein hydrolysate or a conventional adapted cow's milk formula supplemented with 20%of the casein hydrolysate. The minimum duration ofstudy formula exposure was 60 days by6 to 8 months ofage. MAINOUTCOMES ANDMEASURES Primary outcome was type 117 diabetes diagnosed according to World Health Organization criteria. Secondary outcomes included age at diabetes diagnosis and safety (adverse events). RESULTS Among 211759 newborn infants (11702117 female [47.3%]) who were randomized, 117744 (80.8%) completed the trial. The participants were observed for a median of 117117.5 years (quartile [Q] 117-Q3, 1170.2-1172.8). The absolute risk of type 117 diabetes was 8.4% among those randomized tothe casein hydrolysate (n = 9117) vs 7.6% among those randomized to the conventional formula (n = 82) (difference, 0.8% [95% CI, -117.6% to 3.2%]). The hazard ratio for type 117 diabetes adjusted for human leukocyte antigen risk group, duration of breastfeeding, duration of study formula consumption, sex, and region while treating study center as a random effect was 117.117 (95% CI, 0.8 to 117.5; P =.46). The median age at diagnosis of type 117 diabetes was similar in the 2 groups (6.0 years [Q117-Q3, 3.117-8.9] vs 5.8 years [Q117-Q3, 2.6-9.117]; difference, 0.2 years [95% CI, -0.9 to 117.2]). Upper respiratory infections were the most common adverse event reported (frequency, 0.48 events/year in the hydrolysate group and 0.50 events/year in the control group). CONCLUSIONS AND RELEVANCE Among infants at risk for type 117 diabetes, weaning to a hydrolyzed formula compared with a conventional formula did not reduce the cumulative incidence of type 117 diabetes after median follow-up for 117117.5 years. These findings do not support a need to revise the dietary recommendations for infants at risk for type 117 diabetes